Literature DB >> 11065222

Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women.

S Marchesi1, G Lupattelli, D Siepi, G Schillaci, G Vaudo, A R Roscini, H Sinzinger, E Mannarino.   

Abstract

Endothelial dysfunction represents the earliest stage of atherosclerosis and is usually present in hypercholesterolemia. Treatment with statins has been shown to normalize endothelial function in middle-aged men with hypercholesterolemia. We evaluated the effect over time of atorvastatin on the endothelial reactivity in postmenopausal hypercholesterolemic women (mean age, 58 +/- 6 years), receiving atorvastatin, 10 mg daily (n = 20) or American Heart Association step 1 diet (n = 10) for 8 weeks. Lipid profile and brachial artery flow-mediated vasodilation (FMV) were determined at baseline and after 1, 2, 4, and 8 weeks. FMV increased progressively in subjects treated with atorvastatin, and the difference was significant (p < 0.05 vs. baseline) after the second week (baseline 3.8 +/- 3%; first week, 4.8 +/- 3%; second week, 9.2 +/- 3%; fourth week, 11.0 +/- 3%; eighth week, 11.7 +/- 3%). No significant changes were observed in subjects receiving diet (baseline, 3.1 +/- 4%; first week, 2.4 +/- 2%; second week, 2.9 +/- 2%; fourth week, 3.1 +/- 2%; eighth week, 3.3 +/- 2%; p = NS). In the atorvastatin group, low-density lipoprotein (LDL) cholesterol showed a significant decrease since the first week (baseline, 228 +/- 37 mg/dl; first week, 171 +/- 32; second week, 147 +/- 27; fourth week, 139 +/- 29; eighth week, 135 +/- 27; all p < 0.05). In the control group, LDL cholesterol showed a smaller but significant (p < 0.05) reduction after the second week (baseline, 226 +/- 17 mg/dl; first week, 225 +/- 16; second week, 220 +/- 17; fourth week, 203 +/- 27; eighth week, 198 +/- 27). In conclusion, hypercholesterolemic women treated with atorvastatin show a significant improvement in endothelial reactivity after as early as 2 weeks of therapy. The extent to which these beneficial effects are attributable to cholesterol reduction or to a direct effect of the drug remains to be established.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11065222     DOI: 10.1097/00005344-200011000-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  25 in total

Review 1.  Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.

Authors:  H S Malhotra; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Molecular biology of atherosclerosis.

Authors:  Elmo Mannarino; Matteo Pirro
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

Review 4.  Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.

Authors:  R Preston Mason
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome.

Authors:  Dagmar Vondrakova; Petr Ostadal; Andreas Kruger
Journal:  Lipids Health Dis       Date:  2010-07-14       Impact factor: 3.876

6.  Statins as first-line therapy for acute coronary syndrome?

Authors:  Petr Ostadal
Journal:  Exp Clin Cardiol       Date:  2012

Review 7.  Effects of atorvastatin on the different phases of atherogenesis.

Authors:  Paolo Rubba
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin.

Authors:  Chirapa Puntawangkoon; Tim M Morgan; David M Herrington; Craig A Hamilton; W Gregory Hundley
Journal:  Menopause       Date:  2010 Jan-Feb       Impact factor: 2.953

Review 9.  Lipid-lowering therapies in the management of acute coronary syndromes.

Authors:  Lori Mosca; Angelo Biviano
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

10.  Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?

Authors:  Petr Ostadal; David Alan; Jiri Vejvoda
Journal:  Exp Clin Cardiol       Date:  2005
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.